
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
about 4 years ago
ESG: Applying Lessons From Consumer Marketabout 4 years ago
21st Annual Industry Audit: Pharma Performance Checkabout 4 years ago
The Manufacturing Edge on Path to Marketabout 4 years ago
How Good is a Good Product Launch?about 4 years ago
More Than a Name: Vyvgartabout 4 years ago
Fighting Vision Loss: Vabysmoabout 4 years ago
A Sleeping Giant?: Quviviqabout 4 years ago
Next-level Efficacy: Mounjaro




